Last reviewed · How we verify

NCT05219084

Hip Denervation and Intra-articular Hydration in Damaged Hip in Axial Spondyloarthritis Patients

Completed Phase 3 Last updated 3 May 2022
What this trial tests

Phase 3 trial testing hip denervation in Patients With Axial SpA According to ASAS Criteria in 60 participants. Completed in 15 April 2022.

Timeline
1 December 2021
Primary endpoint
15 April 2022
15 April 2022

Quick facts

Lead sponsorSohag University
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date1 December 2021
Primary completion15 April 2022
Estimated completion15 April 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

18 and older, any sex, with Patients With Axial SpA According to ASAS Criteria or Patients With Unilateral or Bilater Hip Damage According to BASRI Score. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: The hip joint is frequently affected in axial spondyloarthritis (SpA) of adults with destructive effects in untreated patients. About 35% of axial SpA patients had either unilateral or bilateral hip arthritis. Destruction is more common with early-onset, active disease, or enthesitis. Objectives: The aim of this study is to evaluate the effect of hip denervation (HD) and intra-articular hydration (IAH) on pain, function score, hip mobility scores in a cohort of axial SpA patients with grade 3 and 4 hip BASRI scores.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05219084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing